New insider activity at Voyager Therapeutics ( (VYGR) ) has taken place on April 5, 2025.
In recent transactions involving Voyager Therapeutics stock, CMO Toby Ferguson sold 10,086 shares, amounting to a total of $34,594. Meanwhile, President & CEO Alfred Sandrock sold 10,885 shares, with the sale valued at $37,335.
Recent Updates on VYGR stock
Voyager Therapeutics has recently experienced a change in its stock price target, primarily due to its Q4 earnings report and financial performance. Canaccord lowered the price target for Voyager from $14 to $12, citing discrepancies in operating expenses and collaboration revenue compared to estimates. The operating expenses were reported at $44.6 million versus an estimate of $43.0 million, while collaboration revenue was $6.3 million against a $10.0 million estimate. These variances were attributed to the timing of R&D activities, which are challenging to predict. Despite these financial setbacks, Voyager’s earnings call highlighted significant advancements in its tau-targeting therapies, a strong cash position, and potential substantial milestone payments from partnerships, indicating a promising future. The company’s strategic focus on tau-targeted therapies and collaborations, particularly with Neurocrine, continues to support its growth prospects.
More about Voyager Therapeutics
YTD Price Performance: -47.91%
Average Trading Volume: 369,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $171.7M